Does functional outcome in acute ischaemic stroke patients correlate with the amount of free-radical scavenger treatment?: A retrospective study of edaravone therapy

Clinical Drug Investigation

Volumn 30, Issue 3, 2010, Pages 143-155

  Unno, Yoshiko ^a,b   Katayama, Makiko ^a   Shimizu, Hideaki ^a  

^a Kawakita General Hospital   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTITHROMBOCYTIC AGENT; ARGATROBAN; NORPHENAZONE; OZAGREL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; CONVALESCENCE; DRUG USE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTIPYRINE; CEREBRAL INFARCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; HUMANS; JAPAN; LENGTH OF STAY; RECOVERY OF FUNCTION; REHABILITATION CENTERS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77249125873     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11535500-000000000-00000     Document Type: Article

References (48)

1. Ministry of Health, Labour and Welfare. Trends in leading causes of death: summary of vital statistics. Tokyo: Statistics and Information Department Minister's Secretariat Ministry of Health, Labour and Welfare, 2009 Oct 22
2. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 1986; 43: 71-84
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988
4. Yamaguchi T. Intermediate results of the post-marketing survey of rt-PA [in Japanese]. Jpn J Stroke 2008; 30: 760-763
5. Tei H. Frequency and its annual change of usage of antithrombotic agent and edarabone according to stroke subtype. Stroke databank [in Japanese]. Tokyo: Nakayama Shoten Company, Limited, 2005: 80-81
6. Yamamoto Y, Kuwahara T, Wanatabe K, et al. Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one. Redox Rep 1996; 2: 333-338
7. Watanabe T, Morita I, Nishi H, et al. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988; 33: 81-87
8. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988; 19: 480-485
9. Yamamoto T, Yuki S, Watanabe T, et al. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res 1997; 762: 240-242
10. The Edaravone Acute Brain Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction: randomized, placebo-controlled, doubleblind study at multicenters. Cerebrovasc Dis 2003; 15: 222-229
11. Joint Committee on Guidelines for the Management of Stroke. Japanese guidelines for the management of stroke 2009 [in Japanese]. Tokyo: Kyowa Kikaku, 2009
12. Mitsubishi Tanabe Pharma Corporation. Radicut (edaravone) prescribing information [in Japanese]. Osaka: Mitsubishi Tanabe Pharma Corporation, 2009
13. Naritomi H. Research on the influences of muscle atrophy preventive therapy starting from the acute phase of cerebral infarction on chronic phase motor function [in Japanese]. Health Labour Science Research Grant, Comprehensive Research on Aging and Health. 2007 Overview Study Rep 2008. Osaka: Ministry of Health, Labour andWelfare of Japan, 2008
14. Kageyama M, Toriyama S, Tsuboshita A, et al. A postmarketing drug use survey of a neuroprotective drug Radicut injection 30 mg (nonproprietary name: edaravone) for acute ischemic stroke [in Japanese]. J New Rem Clin 2009; 58: 1212-1226
15. Okamura S, Kobayashi R, Sakamaki T. Case-mix payment in Japanese medical care. Health Policy 2005; 74: 282-286
16. Yasunaga H, Ide H, Imamura T, et al. Influence of Japan's new diagnosis procedure combination-based payment system on the surgical sector: does it really shorten the hospital stay? Surg Today 2006; 36: 577-585
17. Muranaga F, Kumamoto I, Uto Y, et al. Development of hospital data warehouse for cost analysis of DPC based on medical costs. Methods Inf Med 2007; 46: 679-685
18. Fushimi K, Hashimoto H, Imanaka Y, et al. Functional mapping of hospitals by diagnosis-dominant case-mix analysis. BMC Health Serv Res 2007; 7: 50
19. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke definitions for use in a multicenter clinical trial. Stroke 1993; 24: 35-41
20. Keith RA, Granger CV, Hamilton BB, et al. The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil 1987; 1: 6-18
21. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Maryland State Med J 1965 Feb; 14: 61-65
22. Ueno Y, Zhang N, Miyamoto N, et al. Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model. Neuroscience 2009; 162: 317-327
23. Shinohara Y, Saito I, Kobayashi S, et al. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet Agent) in acute noncardioembolic ischemic stroke (EDO Trial). Cerebrovasc Dis 2009; 27: 485-492
24. Kikuchi K, Tancharoen S, Matsuda F, et al. Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. Biochem Biophys Res Commun 2009; 390: 1121-1125
25. Toyoda K, Fujii K, Kamouchi M, et al. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci 2004 Jun 15; 221 (1-2): 11-17
26. Yamaguchi S, Takahashi K, Kobayashi S. Thrombolytic therapy and cerebroprotecting drug (edaravone) coadministration therapy: stroke databank [in Japanese]. Tokyo: Nakayama Shoten Company, Limited, 2005: 98-99
27. Yamada K, Yoshikawa Y, Nishimura S, et al. Do antithrombotic drug and edaravone combined therapies serve to decrease the frequency of progressive lacuna infarction? Jpn J Stroke 2007; 28: 652-654
28. Mishina M, Komaba Y, Kobayashi S, et al. Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction. Neurol Med Chir (Tokyo) 2005; 45 (7): 344-348
29. Matsumoto S, Horio S, Matayoshi S, et al. Therapy of acute cerebral infarction influencing convalescent rehabilitation: focusing on cerebroprotective drug, edaravone [abstract]. Jpn J Rehab Med 2005; 42 (6): 429
30. Goto F. Official announcement of Japan Stroke Scale. Jpn J Stroke 1997; 19: 1-5
31. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994; 25: 2220-2226
32. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607
33. Wang PY, Kao CH, Mui MY, et al. Leukocyte infiltration in acute hemispheric ischemic stroke. Stroke 1993; 24: 236-240
34. Kawase T, Mizukami M, Tazawa T, et al. Dynamic pathophysiology of cerebral infarction and revascularization. I: ischemic cerebral edema [in Japanese]. No To Shinkei 1982; 34: 1077-1083 (Pubitemid 13173481)
35. Lodder J, Krijne-Kubat B, van der Lugt PJ. Timing of autopsyconfirmed hemorrhagic infarction with reference to cardioembolic stroke. Stroke 1988; 19: 1482-1484
36. Suzuki K. Pathology of cardioembolic stroke [in Japanese]. Ther Res 2000; 3: 403-408
37. Houkin K, Ueno K, Tada M, et al. Arterial recanalization in acute stage of cerebral infarction [in Japanese]. Neurol Med Chir (Tokyo) 1987; 27: 295-301
38. Peters O, Back T, Lindauer U, et al. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1998; 18: 196-205
39. Furuya D, Tanahashi N, Araki N, et al. Edaravone therapy initiated immediately after cardioembolic stroke and its effects on functional recovery. Jpn J Stroke 2006; 28: 291-296
40. Yamamoto Y, Ohara T, Hamanaka M, et al. Predictive factors for progressive motor deficits in penetrating artery infarctions in two different arterial territories. J Neurol Sci 2010 Jan 15; 288: 170-174
41. Clavier I, HommelM, Besson G, et al. Long-term prognosis of symptomatic lacunar infarcts: a hospital-based study. Stroke 1994; 25: 2005-2009
42. Samuelsson M, Sö derfeldt B, Olsson GB. Functional outcome in patients with lacunar infarction. Stroke 1996; 27: 842-846
43. Hassaballa H, Gorelick PB, West CP, et al. Ischemic stroke outcome: racial differences in the trial of danaparoid in acute stroke (TOAST). Neurology 2001; 57: 691-697
44. Uno M, Kitazato K, Suzue A, et al. Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction. Free Radical Biol Med 2005; 39: 1109-1116
45. Inouye M. Predicting models of outcome stratified by age after first stroke rehabilitation in Japan. Am J Phys Med Rehabil 2001; 8: 586-591
46. Musicco M, Emberti L, Nappi G, et al. Early and long-term outcome of rehabilitation in stroke patients: the role of patient characteristics, time of initiation, and duration of interventions. Arch Phys Med Rehabil 2003; 84: 551-558
47. Ng YS, Stein J, Salles SS, et al. Clinical characteristics and rehabilitation outcomes of patients with posteriar cerebral artery stroke. Arch Phys Med Rehabil 2005; 86: 2138-2143
48. Ergreletzis D, Kevorkian CG, Rintala D. Rehabilitation of the older stroke patient: functional outcome and comparison with younger patients. Am J Phys Med Rehabil 2002; 81: 881-889